Silence Therapeutics PLC

Receive alerts
Market Cap:
£293.1 m
374.00 GBX
52 weeks high
52 weeks low

In brief

Silence Therapeutics develops a new generation of medicines by harnessing the body’s natural mechanism of RNA interference, or RNAi, within its cells.

Our proprietary technology can selectively inhibit any gene in the genome, specifically silencing the production of disease-causing proteins. Using our enabling delivery systems, we have achieved an additional level of specificity by delivering our therapeutic RNA molecules exclusively to target cells. Silence’s proprietary RNA chemistries and delivery systems are designed to improve the stability of our molecules and enhance effective delivery to target cells, providing a powerful modular technology well suited to tackle life-threatening diseases.

Deep dive We explore the investor case for growth companies


  • Strong pipeline of pre-clinical drug candidates 
  • Moving into the clinical trial phase later this year
  • Major collaboration with US biopharma Mallinckrodt

Insight Widest with the analysis, Proactive gives perspectives that others don't.

If you want to hit it big (or fail spectacularly), speculate in resource stocks and biotechs

One has to kiss a lot of frogs before one finds oneself puckering up to a prince

3 weeks, 4 days ago